BioWorld

Sep. 8, 2008

View Archived Issues

Acucela Getting $5M Up Front from Otsuka for Vision Drug

Acucela Inc. said it will receive $5 million up front and up to $258 million in milestone payments in a deal with Japan's Otsuka Pharmaceutical Co. Ltd. to co-develop the U.S. biotech's product for vision loss. (BioWorld Today) Read More

FDA to List Drugs of Concern in Public Quarterly Reports

Read More

Control siRNA May Conflate Specific, Nonspecific Effects

Read More

FDA Reviewers Raise Concerns for Death with Ligand's Fablyn

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Financings Roundup

Read More